Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACINIV CBZ
- Development stage
- Unknown
- Lead developer
- Vin Medicament
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACINIV CBZ is a fixed-dose combination medication containing aceclofenac and carbamazepine, developed and marketed by Vin Medicament. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of prostaglandins. Carbamazepine is an anticonvulsant and analgesic that stabilizes hyperexcited nerve membranes by blocking voltage-gated sodium channels, making it particularly effective for neuropathic pain conditions such as trigeminal neuralgia. This oral combination is indicated for the management of pain and inflammation, especially in cases where both inflammatory and neuropathic pain components are present.
- Brand names
- ACINIV CBZ
- Other names
- aceclofenac + carbamazepine
02
Targets
NaV (Voltage-gated sodium channels)Kir (Inward-rectifier potassium channels)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AChR (Acetylcholine receptor)
Beyond the preview
Go deeper on ACINIV CBZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACINIV CBZ.